Evaluation of live attenuated S79 mumps vaccine effectiveness in mumps outbreaks： a matched case-control study

• Published in: Chinese medical journal Vol. 122; no. 3; pp. 307 - 310
• Main Authors: Fu, Chuan-xi, Nie, Jun, Liang, Jian-hua, Wang, Ming
• Format: Journal Article
• Language: English
• Published: China Guangzhou Center of Disease Control and Prevention, Guangzhou, Guangdong 510080, China 05.02.2009
• Subjects: Case-Control Studies; Child; Child, Preschool; China - epidemiology; Female; Humans; Infant; Male; Mumps - epidemiology; Mumps - immunology; Mumps Vaccine - immunology; Vaccines, Attenuated - immunology; 流行性腮腺炎减毒活疫苗; 疫苗剂量; 病例对照研究; 维生素E琥珀酸酯; 腮腺炎疫苗; 计划免疫管理; China; mumps; outbreaks; case-control studies
• ISSN: 0366-6999; 2542-5641
• DOI: 10.3760/cma.j.issn.0366-6999.2009.03.013

Background Mumps virus infection is a potentially serious viral infection of childhood and early adulthood. In China, live attenuated S79 mumps vaccine has been licensed for pediatric use since 1990. The objective of this study was to determine the effectiveness of live attenuated S79 mumps vaccine against clinical mumps in outbreaks. Methods Cases were selected from mumps outbreaks in schools in Guangzhou between 2004 and 2005. Each case was matched by gender, age and classroom. Vaccination information was obtained from Children＇s EPI Administrative Computerized System. Vaccine effectiveness （VE） was calculated for 1 or 2 doses of S79 vaccine with 95% confidence intervals （CI）. Results One hundred and ninety-four cases and 194 controls were enrolled into the study. VE of the S79 mumps vaccine for 1 dose versus 0 confer protection 80.4% （95% Cl, 60.0%-90.4%） and VEs against mumps in outbreaks for 1 dose of mumps vaccine are similar among those children aged 4-9 years and aged over 10 years old. Conclusion The live attenuated S79 mumps vaccine can be effective in preventing clinical mumps outbreaks.